Last reviewed · How we verify
Prednisone Oral Product
Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in cells.
Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in cells. Used for Rheumatoid arthritis, Systemic lupus erythematosus, Polymyalgia rheumatica.
At a glance
| Generic name | Prednisone Oral Product |
|---|---|
| Also known as | Rayos |
| Sponsor | Berinstein, Jeffrey |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Prednisone acts as a glucocorticoid receptor agonist, entering cells and binding to cytoplasmic glucocorticoid receptors. This complex translocates to the nucleus where it modulates gene transcription, leading to decreased production of pro-inflammatory cytokines, reduced immune cell proliferation and migration, and suppression of inflammatory responses. These effects make it useful across multiple inflammatory and autoimmune conditions.
Approved indications
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Polymyalgia rheumatica
- Giant cell arteritis
- Asthma
- Chronic obstructive pulmonary disease exacerbations
- Adrenal insufficiency
- Allergic reactions
- Inflammatory bowel disease
Common side effects
- Insomnia
- Increased appetite
- Nervousness or anxiety
- Indigestion or heartburn
- Increased susceptibility to infections
- Osteoporosis (with chronic use)
- Hypertension
- Hyperglycemia
- Mood changes
Key clinical trials
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (PHASE2)
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (PHASE3)
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (PHASE3)
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) (PHASE1, PHASE2)
- Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (PHASE2, PHASE3)
- Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednisone Oral Product CI brief — competitive landscape report
- Prednisone Oral Product updates RSS · CI watch RSS
- Berinstein, Jeffrey portfolio CI